Chimera nano antibody, single-molecule positioning imaging probe and imaging method
By designing the combination of chimeric nano-antibodies with DNA-PAINT imaging probes, the problems of scintillation instability of fluorescent molecules and excessive antibody size in single-molecular localization microscopy technology are solved, and high-precision and high-density intracellular structure imaging are achieved. and quantitative analysis.
Patent Information
- Application Number
- CN202411072634.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-06
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-08-06
AI Technical Summary
Existing single-molecule localization microscopy technology has limitations in protein quantitative analysis and high-resolution labeling, including instability of scintillation of fluorescent molecules, photobleaching problems and labeling errors caused by excessive antibody size, making it difficult to achieve high precision and high density. Quantitative imaging.
A chimeric nanoantibodies were designed to achieve high affinity and 1:1 by combining NbGFPe nanoantibodies, 36 amino acid-length linkers and Nb2 nanoantibodies, and using click chemical modification to form probes imaging with DNA-PAINT. Mark, reduce mark connection error.
High-quality single-molecule localization super-resolution imaging is achieved, which can finely analyze multiple structures in the cell, improving the accuracy and efficiency of quantitative analysis.
Smart Images

Figure CN119019552A_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the field of fluorescence imaging, and in particular to a chimeric nanobody, a single-molecule localization imaging probe, and a single-molecule localization imaging method. Background Art
[0002] As a non-invasive method, fluorescence microscopy can intuitively obtain in situ information of biological samples by using fluorescent molecules to label proteins of interest. However, due to the existence of optical diffraction limit, the resolution of ordinary fluorescence microscopes is about 200nm, which cannot resolve molecular information with high resolution. With the development of super-resolution fluorescence imaging technology, research work related to subcellular life activities based on super-resolution imaging has received widespread attention.
[0003] Super-resolution fluorescence imaging technology, which was born in the early 21st century, has rapidly developed into an indispensable technical means in life science research due to its advantages of nanoscale spatial resolution, and has great potential as a structural biology research method. In 2014, three scientists from the United States and Germany were awarded the "Nobel Prize in Chemistry" for super-resolution optical microscopy technology.
[0004] Super-resolution imaging technology can be divided into stimulated emission depletion microscopy (STED), structured illumination microscopy (SIM) and single-molecule localization imaging technology (SMLM) according to its working principle. In 2019, the famous Chinese scientist Zhuang Xiaowei won the "Science Breakthrough Prize" for developing SMLM and revealing the delicate structures hidden in cells. According to the development in recent years, it is found that SMLM is the most promising technology for subcellular structure analysis.
[0005] Single-molecule localization microscopy (SMLM) technology is widely favored by scientific researchers due to its simple imaging principle and extremely high spatial resolution (generally 20 to 30 nm). SMLM generally includes three categories: photoactivated localization microscopy (PALM), stochastic optical reconstruction microscopy (STORM), and nanoscale point accumulation topography imaging (DNA-PAINT) using the reversible binding of fluorescent molecules to targets. Generally speaking, the principle of SMLM technology is to use wide-field illumination and the blinking properties of fluorescent molecules to activate only some fluorescent molecules in each frame of imaging, collect images at different time points, and reconstruct super-resolution images that break the optical diffraction limit through algorithms.
[0006] At present, researchers have improved and optimized SMLM instrument hardware, image processing algorithms, sample preparation and other aspects, and gradually applied this technology to the field of biology. For example, the use of imaging technologies such as STORM and PALM has successively achieved detailed observation of many subcellular structures such as chromatin, centrioles, nuclear pore complexes, mitochondria, endoplasmic reticulum and cytoskeleton; in addition, these technologies can be used to intuitively and visually obtain the nanoscale spatial distribution and organizational characteristics of important biological macromolecules such as genomic DNA and proteins in cells, so as to conduct a more accurate and comprehensive analysis of the co-localization relationship and interaction network between molecules.
[0007] SMLM data not only contains the spatial position information of fluorophores, but also includes the quantity information of fluorophores (such as the number of localization and blinking dynamics). In order to achieve the goal of quantitative analysis, researchers use the spatiotemporal information of single-molecule localization data to establish complex dye molecule photophysical models for visual quantitative analysis. It can be seen from literature reports that STORM / PALM technology based on conventional dyes or fluorescent protein molecules has certain limitations: First, the blinking and reactivation mechanism of conventional dye molecules is not clear, and there is a photobleaching problem, which will lead to inaccurate counting. There is currently no better solution, which hinders protein quantitative analysis; second, the distribution of proteins in cells is heterogeneous, with a wide range of scales (tens of nanometers to hundreds of nanometers) and various distribution morphologies. It is difficult to achieve high-precision and high-density localization imaging over a large range, and there is an urgent need to develop a variety of quantitative evaluation standards. In situ high-resolution quantitative analysis of target proteins is still in its infancy, and better analytical methods are urgently needed to fill this gap.
[0008] The conventional labeling method is to use the immunofluorescence strategy of antibodies (150kDa). The size of antibodies is about 10nm and they cannot freely enter the cell membrane. Therefore, labeling intracellular proteins requires membrane breaking, which will affect the physiological structure of the sample and cannot achieve high-efficiency labeling. In addition, conventional immunofluorescence uses a primary antibody plus secondary antibody labeling strategy. The distance between the dye molecules on the antibody and the target protein molecules is large, which will cause a large connection error and reduce the resolution of single-molecule localization. At present, in order to reduce the labeling size, a variety of labeling technologies have been developed, including Fab fragment antibodies, nanoantibodies, fluorescent proteins, short peptide tags, SNAP-tag tags, and HaloTag tags, all of which can control the labeling size below 5nm.
[0009] Thanks to genetic recombination technology, multiple labeling methods mediated by nanoantibodies provide a simple and universal method to label a variety of GFP and RFP-derived fusion structures, which can be used for advanced single-molecule imaging applications. With the continuous update of single-molecule localization super-resolution imaging technology, researchers have put forward higher requirements for the use of nanoantibody labeling, requiring not only antibodies with strong specificity and high affinity, but also quantitative probes that can achieve 1:1 labeling.
[0010] In view of the development of technology and the needs of application, it is very important to develop new and effective nano-antibody probes and establish single-molecule localization super-resolution imaging analysis methods based on them. Summary of the invention
[0011] One of the technical objectives of the present invention is to provide a chimeric nanobody that can be used for single-molecule imaging, which can achieve high-affinity binding while achieving 1:1 labeling, with a smaller labeling connection error, which is conducive to a single-molecule localization super-resolution imaging method for quantitative analysis.
[0012] Another technical purpose of the present invention is to provide a chimeric nanobody single-molecule localization imaging probe.
[0013] Another technical purpose of the present invention is to provide a method for preparing the above-mentioned chimeric nanobody single-molecule localization imaging probe.
[0014] Another technical objective of the present invention is to provide a kit for single-molecule localization imaging.
[0015] Another technical objective of the present invention is to provide a single-molecule localization super-resolution fluorescence imaging method.
[0016] In one aspect, the present invention provides a chimeric nanobody that can be used for single-molecule imaging, which comprises the following sequences from N-terminus to C-terminus:
[0017] NbGFPe nanobody sequence;
[0018] 36 amino acid linker;
[0019] Nb2 nanobody sequence; and
[0020] C-terminal linker containing cysteine.
[0021] In a specific embodiment, the amino acid sequence of the NbGFPe nanobody is: SEQ ID No.: 1.
[0022] In a specific embodiment, the amino acid sequence of the linker with a length of 36 amino acids is: SEQ ID No.: 2.
[0023] In a specific embodiment, the amino acid sequence of the Nb2 nanobody is: SEQ ID No.: 3.
[0024] In a specific embodiment, the amino acid sequence of the cysteine-containing C-terminal linker is: SEQ ID No.: 4 or SEQ ID No.: 5, or the cysteine-containing C-terminal linker is only a single cysteine.
[0025] In a specific embodiment, the amino acid sequence of the chimeric nanobody is SEQ ID No.:6.
[0026] On the other hand, the present invention provides a recombinant protein comprising: the chimeric Nanobody described above; and optionally a tag sequence that assists expression and / or purification.
[0027] In yet another aspect, the present invention provides a polynucleotide encoding the above-mentioned chimeric Nanobody or the above-mentioned recombinant protein.
[0028] In a specific embodiment, the nucleotide sequence of the polynucleotide is SEQ ID No.:9.
[0029] In yet another aspect, the present invention provides a recombinant expression vector comprising the above-mentioned polynucleotide.
[0030] In yet another aspect, the present invention provides a transformant comprising the polynucleotide or the recombinant expression vector.
[0031] In another aspect, the present invention provides a chimeric nanobody single-molecule localization imaging probe, comprising:
[0032] The chimeric nanobody described above;
[0033] A DNA sequence for DNA-PAINT imaging, whose nucleotide sequence is SEQ ID No.: 7 or SEQ ID No.: 8; and
[0034] A linking group for connecting the chimeric nanobody and the DNA sequence for DNA-PAINT imaging.
[0035] In the chimeric nanobody single-molecule localization imaging probe according to the present invention, the chimeric nanobody and the DNA sequence for DNA-PAINT imaging can be connected by any suitable linking group without particular limitation. For example, the linking group can be connected to the chimeric nanobody at one end through the thiol group at the end of the chimeric nanobody, and connected to the 3' end of the DNA sequence for DNA-PAINT imaging at the other end.
[0036] In a specific embodiment, the linking group has a structure shown in the following formula I:
[0037] *-R-linker1-Mal'-**
[0038] I
[0039] Wherein, R represents a linking group formed by an amino-reactive group or click chemistry, examples of which may be a group formed by the reaction of DBCO and azide, a group formed by the reaction of TCO and Tz, and an amide group formed by the reaction of NHS ester and amino group; Linker1 represents a C2-C10 alkylene group, which may optionally additionally contain an ester group, an amide group and / or a PEG chain represented by -(CH2CH2O)n- in its main chain, wherein n is selected from an integer of 1-10, for example, n is 3 or 4,
[0040] Mal' indicates
[0041] * indicates the position linked to the 3' end of the DNA sequence, and ** indicates the position linked to the chimeric Nanobody.
[0042] In a specific embodiment, the linking group is selected from
[0043]
[0044] In a specific embodiment, the chimeric nanobody single-molecule localization imaging probe has the structure shown below:
[0045]
[0046] In the above structures, represents the chimeric nanobody part, Represents a DNA sequence portion.
[0047] In another aspect, the present invention provides a method for preparing the above-mentioned chimeric nanobody single-molecule localization imaging probe. The method can be carried out in any suitable manner. For example, the chimeric nanobody according to the present invention can be first reacted with a linker to obtain a chimeric nanobody with a linker, and then the chimeric nanobody with a linker is reacted with a DNA sequence for DNA-PAINT imaging to obtain a chimeric nanobody single-molecule localization imaging probe according to the present invention; or the DNA sequence for DNA-PAINT imaging can be first reacted with a linker to obtain a DNA sequence with a linker, and then the DNA sequence with a linker is reacted with the chimeric nanobody according to the present invention to obtain a chimeric nanobody single-molecule localization imaging probe according to the present invention, or the chimeric nanobody according to the present invention and the DNA sequence for DNA-PAINT imaging can be reacted with a linker at the same time to obtain a chimeric nanobody single-molecule localization imaging probe according to the present invention. Therefore, the linker carries a first reactive group for reacting with the chimeric nanobody according to the present invention, and a second reactive group for reacting with the DNA sequence for DNA-PAINT imaging. The first reactive group and the second reactive group can be designed and selected with reference to the reactive groups that the chimeric Nanobody according to the present invention has or can form and the reactive groups that the DNA sequence used for DNA-PAINT imaging has or can form.
[0048] In some embodiments, the first reactive group of the linker is a succinimide group, and the second reactive group is selected from functional groups commonly used in click chemistry, such as an azido group, an alkynyl group, a dibenzocyclooctyne (DBCO) group, a trans-cyclooctene (TCO) group, a tetrazine (Tz) group, a bicyclo [6,1,0] nonynyl group, an N-hydroxysuccinimide (NHS) group, etc., but are not limited thereto.
[0049] In a specific embodiment, the method comprises the following steps:
[0050] S1: reducing the chimeric nanobody to obtain a chimeric nanobody with a free thiol group;
[0051] S2: reacting the chimeric nanobody obtained in S1 with a cross-linking agent shown in the following formula II to obtain a chimeric nanobody connected with a cross-linking agent, wherein the thiol group on the chimeric nanobody reacts specifically with the maleimide group in the cross-linking agent to form an irreversible thioether bond:
[0052] R2-linker1-Mal
[0053] II
[0054] In Formula II, R2 represents a reactive group, such as an amino reactive group or a click chemistry reactive group;
[0055] Linker1 is as defined in Formula I above,
[0056] Mal said
[0057] S3: The reaction product of S2 is reacted with a nucleic acid sequence for DNA-PAINT imaging having a reactive group R3 of the following formula II to obtain a chimeric nanobody probe modified with DNA, namely the chimeric nanobody single-molecule localization imaging probe.
[0058] R3-DNA
[0059] II
[0060] In Formula II, R3 represents a group that can react with the above R2 to produce a connection; the DNA sequence is selected from SEQ ID No.: 7 or SEQ ID No.: 8, wherein the nucleotides in the above DNA sequence can be left-handed nucleotides or right-handed nucleotides.
[0061] In a specific embodiment, R2 is a dibenzocyclooctyne (DBCO) group and R3 is an azide group; or R2 is a trans-cyclooctene (TCO) group and R3 is a tetrazine (Tz) group; or R2 is an N-hydroxysuccinimide (NHS) group and R3 is an amino group.
[0062] In a specific embodiment, the cross-linking agent used in S2 is DBCO-PEG4-Maleimide; the nucleic acid sequence used for DNA-PAINT imaging in S3 is SEQ ID No.:7.
[0063] In a specific embodiment, the reaction in S2 can be shown as the following reaction formula 1 or 2:
[0064] Reaction 1:
[0065]
[0066] Reaction 2:
[0067]
[0068] The reaction in S3 can be shown in the following reaction formula 3 or 4, reaction formula 3:
[0069]
[0070] Reaction 4:
[0071]
[0072] In the above reaction formulas, represents the chimeric nanobody part, Represents the nucleic acid sequence portion.
[0073] In a specific embodiment, the reducing agent used in S1 is selected from tris(2-carboxyethyl)phosphine hydrochloride (TCEP) solution.
[0074] In a specific embodiment, in S2, the molar ratio of the cross-linking agent to the reduced chimeric Nanobody is about 5-20.
[0075] In a specific embodiment, in S3, the molar ratio of the nucleic acid sequence for DNA-PAINT imaging to the chimeric nanobody linked to a cross-linker is 3-10.
[0076] In a specific embodiment, the preparation method may further comprise a purification step S4 to purify the chimeric nanobody probe modified with DNA of S3. In S4, the chimeric nanobody probe modified with DNA of S3 may be purified by molecular sieve and ion exchange technology.
[0077] In a specific embodiment, in S1-S3, the reaction temperature is 4°C; the reaction time of S1 is 0.5h to 2h; the reaction time of S2 is 2h to 16h; and the reaction time of S3 is 1h to 16h.
[0078] In yet another aspect, the present invention provides a kit comprising: the above-mentioned chimeric nanobody single-molecule localization imaging probe, and a DNA imaging chain with a fluorescent dye.
[0079] In a specific embodiment, the DNA imaging strand refers to a DNA sequence with a fluorescent dye and a quencher group at both ends, and the sequence may be SEQ ID No.: 10 or SEQ ID No.: 11; the fluorescent dye may be Cy3B or ATO643, and the quencher group may be BHQ2 or BBQ650. The DNA imaging strand with the fluorescent dye may be customized by a primer synthesis company, and may be synthesized from a right-handed base raw material or a left-handed base raw material.
[0080] In a specific embodiment, the sequence of the DNA imaging strand with fluorescent dye is SEQ ID No.: 10. This sequence is specially designed for the DNA-PAINT imaging method, that is, the imaging sequence and the docking sequence are not completely complementary, so that the sequence can be directly combined and detached quickly, and the fast reaction kinetics can be achieved, which can effectively realize fast low-background single-molecule localization super-resolution imaging.
[0081] In another aspect, the present invention provides a method for performing DNA-PAINT super-resolution imaging, the method comprising the following steps:
[0082] S1': fixed biological sample containing green fluorescent protein;
[0083] S2': Block and permeabilize the fixed biological sample of S1';
[0084] S3': adding the above chimeric nanobody single-molecule localization imaging probe to incubate the biological sample of S2';
[0085] S4': washing the biological sample of S3' with PBS buffer; and
[0086] S5': Add the above-mentioned DNA imaging strand with fluorescent dye to the biological sample of S4' to perform single-molecule localization super-resolution imaging.
[0087] The labeling method of the present application is not limited by cell lines, and in theory, biological samples with green fluorescent protein labels can be well labeled. There is no restriction on the fixation method of different biological samples, and those skilled in the art can choose to implement the best structural fixation scheme for different biological samples. There is no restriction on the closed and permeabilized treatment method of different biological samples, and those skilled in the art can choose to implement the best closed and permeabilized treatment method for different biological samples.
[0088] In a specific embodiment, the biological sample is a cell, and the method is used to perform DNA-PAINT super-resolution imaging of organelles in the cell, including endoplasmic reticulum, nuclear pore complex, microtubule, Golgi, clathrin, mitochondria, etc.
[0089] The present invention can be used not only for conventional labeling imaging of organelles expressing green fluorescent protein, but also for biological tissue samples carrying green fluorescent protein.
[0090] Beneficial Effects
[0091] The present invention designs two single nanobodies into a novel chimeric nanobody through gene recombination technology, effectively avoiding the problems of low affinity and multi-site labeling of single antibodies, and can achieve 1:1 high affinity labeling. The gene sequence modified by the method of the present invention can obtain a chimeric nanobody corresponding to the molecular weight after induced expression, and further obtain a probe for DNA-PAINT super-resolution imaging through site-specific and click chemistry modification, which can obtain high-quality images for imaging of various fine structures in cells. BRIEF DESCRIPTION OF THE DRAWINGS
[0092] Figure 1 : Schematic diagram of the construction of the chimeric nanobody single-molecule localization imaging probe of the present invention and single-molecule localization super-resolution fluorescence imaging for quantitative analysis.
[0093] Figure 2 : Schematic diagram of site-specific modification of chimeric nanobodies.
[0094] Figure 3 : Chimeric nanobody modified DNA chromatography purification diagram (molecular sieve SEC and ion exchange chromatography IEX) and SDS-PAGE verification diagram.
[0095] Figure 4 : Schematic diagram of endoplasmic reticulum super-resolution imaging of two different chimeric nanobodies.
[0096] Figure 5 : Super-resolution imaging of different antibodies on nuclear pore complex structure markers. DETAILED DESCRIPTION
[0097] In order to better understand the present invention, the content of the present invention is further explained below in conjunction with embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.
[0098] Material Information:
[0099]
[0100]
[0101] DBCO-PEG4-Maleimide, dibenzocyclooctyne-tetraethylene glycol-maleimide, has the following structural formula:
[0102]
[0103] TCEP, the full name is Tris(2-carboxyethyl)phosphine, the structural formula is as follows: It is usually used in the form of its hydrochloride salt.
[0104] TCO-PEG3-Maleimide, trans-cyclooctene-polyethylene glycol-maleimide, has the following structural formula:
[0105]
[0106] Single-molecule localization super-imaging technology has problems with probe labeling size and labeling ratio when quantitatively analyzing fine structures in situ in cells. For the common fusion protein GFP, Ziyue Zhang et al. (Zhang, Z., Wang, Y., Ding, Y. et al. Structure-based engineering of anti-GFP nanobody tandems as ultra-high-affinity reagents for purification. Sci Rep 10, 6239 (2020). https: / / doi.org / 10.1038 / s41598-020-62606-7) disclosed a new chimeric nanobody (NbGFPe-LaG16) formed by connecting two different nanobodies, which has high affinity and one-to-one labeling characteristics, but the nanobody has not been implemented in the field of super-resolution imaging. The present invention takes super-resolution imaging probes as the starting point, designs and purifies a new chimeric nanobody such as NbGFP-36AAlinker-Nb2-Cys, which can be used for subsequent site-specific modification of probes for super-resolution imaging, thereby achieving in situ imaging analysis and quantitative analysis of fine structures within cells. The chimeric nanobody (NbGFPe-Nb2) of the present application is substantially different from the antibody (NbGFPe-LaG16) reported in the literature in that it has better imaging effects in the field of super-resolution imaging and has the characteristics of one-to-one labeling while showing better specificity.
[0107] Figure 1 The schematic diagram of the construction of the chimeric nanobody single-molecule localization imaging probe of the present invention and the single-molecule localization super-resolution fluorescence imaging for quantitative analysis is shown. As shown in the figure, the present application first constructs a chimeric nanobody, which comprises a NbGFPe nanobody sequence, a linker of 36 amino acids in length, an Nb2 nanobody sequence, and a C-terminal linker containing cysteine for site-specific modification. On this basis, the chimeric nanobody is connected to a nucleic acid sequence for DNA-PAINT imaging by click chemistry to form a chimeric nanobody single-molecule localization imaging probe. The chimeric nanobody single-molecule localization imaging probe and the designed DNA imaging chain with fluorescent dye are then used to perform DNA-PAINT super-resolution imaging of different organelles in the cell in order to quantitatively analyze the target.
[0108] Example 1: Design, expression and purification of chimeric nanobodies
[0109] In this example, a target protein gene fragment was designed, and then the target gene fragment was constructed into a pET26b expression vector, transformed into Escherichia coli Rosetta (DE3) to induce protein expression, and purified to obtain the target protein.
[0110] The specific steps are as follows:
[0111] Step 1: The nucleotide sequence information of two separate NbGFPe and Nb2 nanobodies are SEQ ID No.: 12 and 13 respectively;
[0112] NbGFPe: (SEQ ID No.: 12)
[0113] CAGGTCCAACTGGTTGAGTCTGGAGGGGCGTTGGTGCAGCCCGGTGGGAGCCTTCGTCTTTCCTGTGCGGCCAGTGGATTCCCTGTTAACCGTTATAGTATGCGTTGGTATCGTCAAGCTCCTGGCAAAGAGCGTGAATGGGTGGCCGGAATGTCATCGGCCGGCGATCGCA GTAGTTACGAAGATTCGGTTAAAGGCCGTTTCACCATTAGTCGTGACGACGCCCGTAACACGGTTTATCTGCAGATGAATAGTTTAAAACCTGAAGACACAGCAGTATATTATTGCAATGTAAACGTAGGATTCGAATATTGGGGTCAGGGTACACAGGTAACAGTGTCGTCA
[0114] Nb2: (SEQ ID No.: 13)
[0115] CAGGTTCAGTTGCAGGAATCGGGAGGTGGTAGTGTTCAGGCTGGCGGATCGCTGCGCCTTTCCTGCGCGGCCTCCGGGCCCACGTATAGTTCATATTTCATGGCATGGTTCCGTCAAGCCCCCGGTATGGAACGTGAAGGCGTGGCTGCAAGCAGTTACGACGGGAGCACGACATTGTATGCGGACTCAGTA AAGGGCCGCTTCACCATTAGTCAAGGTAATGCTAAGAACACAAAGTTCTTGTTGTTGAATAATCTTGAGCCCGAAGATACGGCGATCTACTATTGTGCTTTACGCCGTCGTGGCTGGTCAAATACGTCGGGCTGGAAACAGCCAGGTTGGTACGACTATTGGGGTCAAGGCACGCAAGTAACCGTCAGTTCT
[0116] Step 2: Design the nucleotide sequence of a linker with a length of 36 amino acids that connects two nanobodies, namely 36AAlinker: SEQ ID No.: 14.
[0117] 36AAlinker: (SEQ ID No.: 14)
[0118] GGCGGTAGTGCTGCTTCCGGTGGAGCATCAGCTAGTGGAGGTACGGGCGGATCCGGAGGGACTTCGGCTTCCGGTGCTTCTGCCGGCGGATCCGGTGGAGCTGGTACT
[0119] The final target nucleotide sequence is NbGFPe-36linker-Nb2-Cys (SEQ ID No.: 9).
[0120] The nucleotide sequences of the relevant antibodies used in the control experiment are as follows:
[0121] NbGFPe-Cys: (SEQ ID No.: 15)
[0122] CAGGTCCAACTGGTTGAGTCTGGAGGGGCGTTGGTGCAGCCCGGTGGGAGCCTTCGTCTTTCCTGTGCGGCCAGTGGATTCCCTGTTAACCGTTATAGTATGCGTTGGTATCGTCAAGCTCCTGGCAAAGAGCGTGAATGGGTGGCCGGAATGTCATCGGCCGGCGATCGCAGTAGTTACGAAGATTCGGTTAAAGGCCGTTTCACCATTAGTCGTGACGACGCCCGTAACACGGTTTATCTGCAGATGAATAGTTTAAAACCTGAAGACACAGCAGTATATTATTGCAATGTAAACGTAGGATTCGAATATTGGGGTCAGGGTACACAGGTAACAGTGTCGTCAAAGGATGACAAATCCTGCGGCAAAGACAAAGAT
[0123] Nb2-Cys:(SEQ ID No.:16)
[0124] CAGGTTCAGTTGCAGGAATCGGGAGGTGGTAGTGTTCAGGCTGGC
[0125] GGATCGCTGCGCCTTTCCTGCGCGGCCTCCGGGCCCACGTATAGTTCAT
[0126] ATTTCATGGCATGGTTCCGTCAAGCCCCCGGTATGGAACGTGAAGGCGT
[0127] GGCTGCAAGCAGTTACGACGGGAGCACGACATTGTATGCGGACTCAGT
[0128] AAAGGGCCGCTTCACCATTAGTCAAGGTAATGCTAAGAACACAAAGTT
[0129] CTTGTTGTTGAATAATCTTGAGCCCGAAGATACGGCGATCTACTATTGTG
[0130] CTTTACGCCGTCGTGGCTGGTCAAATACGTCGGGCTGGAAACAGCCAG
[0131] GTTGGTACGACTATTGGGGTCAAGGCACGCAAGTAACCGTCAGTTCTA
[0132] AGGATGACAAATCCTGCGGCAAAGACAAAGAT
[0133] NbGFPe-36linker-LaG16-Cys:(SEQ ID NO.:17)
[0134] CAGGTCCAACTGGTTGAGTCTGGAGGGGCGTTGGTGCAGCCCGGT
[0135] GGGAGCCTTCGTCTTTCCTGTGCGGCCAGTGGATTCCCTGTTAACCGTT
[0136] TAGTATGCGTTGGTATCGTCAAGCTCCTGGCAAAGAGCGTGAATGGGT
[0137] GGCCGGAATGTCATCGGCCGGCGATCGCAGTAGTTACGAAGATTCGGTT
[0138] AAAGGCCGTTTCACCATTAGTCGTGACGACGCCCGTAACACGGTTTATC
[0139] TGCAGATGAATGTTTAAAACCTGAAGACACAGCAGTATTATTGCAA
[0140] TGTAAACGTAGGATTCGAATATTGGGGTCAGGGTACACAGGTAACAGTG
[0141] TCGTCAGGCGGTAGTGCTGCTTCCGGTGGAGCATCAGCTAGTGGAGGT
[0142] ACGGGCGGATCCGGAGGGACTTCGGCTTCCGGTGCTTCTGCCGGCGGA
[0143] TCCGGTGGAGCTGGTACTCAGGTGCAACTTGTTGAAAGTGGAGGGCGT
[0144] CTTGTGCAAGCGGGTGATAGTTTACGTCTTAGTTGTGCCGCTAGCGGGC
[0145] GCACATTCAGTACATCTGCTATGGCTTGGTTTCGTCAAGCACCAGGCCG
[0146] TGAGCGCGAGTTCGTGGCGGCTATCACGTGGACTGTGGGTAATACTATC
[0147] TTAGGAGACAGCGTTAAGGGCCGCTTCACCATCAGTCGTGACCGCGCC
[0148] AAAAATACAGTAGATCTGCAGATGGACAATTTGGAGCCTGAGGATACA
[0149] GCTGTATATTATTGTAGCGCACGTAGCCGTGGCTACGTTCTTGTCTGTTCT
[0150] GCGCTCTGTCGACTCTTATGATTATTGGGGTCAAGGCACGCAAGTGACT
[0151] GTGTCTAGCAAGGATGACAAATCCTGCGGCAAAGACAAAGAT
[0152] Step 3: construct the sequence in the above step 2 into the pET26b expression vector, then transform it into Escherichia coli Rosetta (DE3) to induce protein expression, and purify to obtain the target protein.
[0153] The specific operation process of construction-transformation-induction expression is as follows:
[0154] (1) After synthesizing the gene fragment, it is connected to the pET26b expression vector, and the resulting ligation product has kanamycin resistance;
[0155] (2) The ligation product was transformed into E. coli DH5α competent cells and spread on a solid LB plate with kanamycin resistance, and inverted in a 37°C incubator for 12 to 14 hours;
[0156] (3) Single colonies on the solid LB plate are selected and sent to a sequencing company for sequencing. After the sequencing results come out, they are compared with the designed sequence to ensure that the sequencing results are correct;
[0157] (4) The correctly sequenced plasmid was transformed into Escherichia coli Rosetta (DE3) competent cells and spread on a solid LB plate with kanamycin resistance, and inverted in a 37°C incubator for 12 to 14 hours;
[0158] (5) Select a single colony on the plate in step (4) and inoculate it into 50 mL of LB liquid culture medium containing kanamycin resistance, and culture it in a constant temperature shaker at 37°C and 220 rpm for 12 to 14 hours.
[0159] (6) Transfer the bacterial culture medium in step (5) to 2 L of 2×YT (Formedium) liquid medium and shake the culture to amplify until the OD600 is about 0.8. After cooling, add IPTG to a final concentration of 0.5 mM and induce at 220 rpm at 22°C for 16 hours.
[0160] (7) Centrifuge at 8000 rpm for 20 min to collect the cells;
[0161] (8) Lysing bacteria by osmotic shock to release proteins, and using histidine tag technology and affinity chromatography purification methods to achieve preliminary purification of chimeric nanobodies;
[0162] (9) further purifying the antibody product obtained in step (8) using molecular sieve chromatography technology;
[0163] Example 2: Site-specific modification of chimeric nanobodies
[0164] like Figure 2 As shown in , the chimeric Nanobody obtained in Example 1 above was site-specifically modified.
[0165] The specific experimental process is as follows:
[0166] (1) The chimeric nanobody obtained in Example 1 was replaced by ultrafiltration into a phosphate buffer containing a reducing agent (1×PBS+1mM EDTA+3mM TCEP) and reacted at 4°C for 30 min;
[0167] (2) replacing the reduced chimeric nanobody buffer in step (1) with a phosphate buffer solution PB at a pH of 6.8 (PB: 8.1 mM Na2HPO4, 1.5 mM KH2PO4, 137 mM NaCl, 2.7 mM KCl, pH = 6.8), and then adding a cross-linking reagent DBCO-PEG4-Maleimide, reacting at 4°C for 2 hours at a molar ratio of nanobody to cross-linking agent of 1:20;
[0168] (3) using a 7K desalting column to remove the cross-linking agent in step (2) above, and then using a 10K ultrafiltration tube to replace the buffer with a 1× PBS buffer with a pH of 7.4, and finally reacting at 4°C overnight with a molar ratio of 1:10 between the chimeric nanobody and Azide-DNA (5'-3': CCTTCAACATATCCTCTAC-Azide, SEQ ID No.: 7);
[0169] (4) Finally, molecular sieve SEC and ion exchange technology IEX were used to purify the chimeric nanoantibody probe modified with DNA to obtain high purity. SDS-PAGE electrophoresis technology was then used to verify that the purified peak was indeed the target product. The detailed characterization results are shown in Figure 3 The detailed analysis is as follows: the reaction mixture (MIX) corresponds to lane A before purification, and two peaks appear after molecular sieve SEC purification. The first peak (P3, P4, P5 on the SEC graph) corresponds to SDS-PAGE lanes B, C and D, and the second peak (P7 on the SEC graph) corresponds to lane E. Lane E has no bands but has a high-intensity signal value on the molecular sieve map. The results fully show that a large amount of unreacted DNA is removed during the SEC purification process, but the B, C and D bands corresponding to the first peak show a high proportion of unreacted DNA. Therefore, the chimeric nanoantibody decorated with DNA was further purified using ion exchange technology IEX. Lane G is the unmodified chimeric nanoantibody as a control, lane H is the diluted sample of the first peak in the previous step SEC (the impurity protein does not appear obvious), the first peak of IEX (4 on the IEX graph) corresponds to lane I, and the second peak (14 and 15 on the IEX graph) corresponds to lanes J and K. Bands J and K show that the collected product contains a high proportion of chimeric nanoantibodies modified with DNA, indicating that the further purification effect is obvious.
[0170] Example 3: Single-molecule localization super-resolution imaging
[0171] The chimeric nanobody probe obtained in the above Example 2 is applied to label various intracellular organelles, and the labeling of the endoplasmic reticulum and nuclear pore complex is described in detail below.
[0172] (1) Endoplasmic reticulum markers
[0173] The cultured COS-7 cells were inoculated on a cell slide, and when the density grew to about 70%, the plasmid mEmerald-sec61b was transfected into the cells by transient transfection. The cells overexpressed the green fluorescent protein tag mEmerald that could bind to the purified nanobody, and the transfection efficiency was about 70%. The cells were then fixed for 15 minutes with a mixed fixative of 3% paraformaldehyde (PFA) and 0.1% glutaraldehyde (GA). The fixative was removed, the cells were washed three times with 1×PBS buffer, and then the cells were blocked and permeabilized at room temperature for 1 hour. Finally, the chimeric nanobody probe in Example 2 was added to the cells and incubated overnight at 4°C. After washing three times with 1×PBS buffer, a DNA imaging chain PS1 (Cy3B-AGAAGTAATGTGGAA-BHQ2, SEQ ID No.: 10) with a fluorescent dye was added for single-molecule localization super-resolution imaging.
[0174] Based on the above steps, single-molecule localization super-resolution imaging of NbGFPe-LaG16-Cys-DNA was performed to obtain the endoplasmic reticulum super-resolution imaging image of NbGFPe-LaG16-Cys-DNA.
[0175] The results are as follows Figure 4 ,Comparing the endoplasmic reticulum super-resolution imaging images of the two chimeric nanobodies, it was found that the effect of the NbGFPe-Nb2-Cys-DNA probe was significantly better than that of NbGFPe-LaG16-Cys-DNA.
[0176] (2) Nuclear pore complex labeling
[0177] The cultured U-2OS Nup96-mEGFP cells were inoculated onto a cell slide and fixed with a preheated 2.4% PFA solution for 30 min after 48 hours. The fixative was removed and the cells were washed three times with 1×PBS buffer. Then, the cells were treated with a blocking permeabilization reagent (3% BSA@0.25% Triton X-100@1×PBS) at room temperature for 2 hours. Finally, the chimeric nanoantibody probe in Example 2 was added to the cells and incubated at 4°C overnight. After washing three times with 1×PBS buffer, a DNA imaging chain PS1 with a fluorescent dye was added for single-molecule localization super-resolution imaging.
[0178] Based on the above steps, single-molecule localization super-resolution imaging was performed using NbGFPe-Cys-DNA, Nb2-Cys-DNA and a combination of two single nanoantibodies (NbGFPe-Cys-DNA+Nb2-Cys-DNA).
[0179] The results are as follows Figure 5By comparing the super-resolution imaging images of single nanoantibodies and chimeric nanoantibodies, it was found that the effect of the chimeric nanoantibody NbGFPe-Nb2-Cys-DNA probe was significantly better than that of NbGFPe-Cys-DNA and Nb2-Cys-DNA, and was also better than the combination of two single nanoantibodies (NbGFPe-Cys-DNA + Nb2-Cys-DNA).
Claims
1. A chimeric nanobody comprising the following sequences from N-terminus to C-terminus: NbGFPe nanobody sequence; 36 amino acid linker; Nb2 nanobody sequence; and C-terminal linker containing cysteine.
2. The chimeric Nanobody according to claim 1, wherein The amino acid sequence of NbGFPe nanobody is: SEQ ID No.: 1; The amino acid sequence of the linker with a length of 36 amino acids is: SEQ ID No.: 2; The amino acid sequence of the Nb2 nanobody is: SEQ ID No.: 3; The amino acid sequence of the C-terminal linker containing cysteine is: SEQ ID No.: 4 or SEQ ID No.: 5, or the C-terminal linker containing cysteine is only a single cysteine.
3. The chimeric Nanobody according to claim 1, wherein The amino acid sequence of the chimeric nanobody is SEQ ID No.:
6.
4. A recombinant protein comprising: The chimeric Nanobody according to any one of claims 1 to 3; and optionally a tag sequence to facilitate expression and / or purification.
5. A polynucleotide encoding the chimeric Nanobody according to any one of claims 1 to 3 or the recombinant protein according to claim 4.
6. The polynucleotide according to claim 5, whose nucleotide sequence is SEQ ID No.:
9.
7. A recombinant expression vector comprising the polynucleotide according to claim 5 or 6.
8. A transformant comprising the polynucleotide according to claim 5 or 6 or the recombinant expression vector according to claim 7.
9. A chimeric nanobody single-molecule localization imaging probe, comprising: The chimeric Nanobody according to any one of claims 1 to 3; A DNA sequence for DNA-PAINT imaging, whose nucleotide sequence is SEQ ID No.: 7 or SEQ ID No.: 8; and A linking group for connecting the chimeric nanobody and the DNA sequence for DNA-PAINT imaging.
10. The chimeric nanobody single-molecule localization imaging probe according to claim 9, which has the structure shown below: In the above structures, represents the chimeric nanobody part, Represents a DNA sequence portion.
11. The method for preparing the chimeric nanobody single-molecule localization imaging probe according to claim 9, comprising: First, reacting the chimeric Nanobody as described in any one of claims 1 to 3 with a linker to obtain a chimeric Nanobody with a linker, and then reacting the chimeric Nanobody with a linker with a DNA sequence for DNA-PAINT imaging; or First, the DNA sequence for DNA-PAINT imaging is reacted with a linker to obtain a DNA sequence with a linker, and then the DNA sequence with the linker is reacted with the chimeric Nanobody according to any one of claims 1 to 3, or The chimeric Nanobody according to any one of claims 1 to 3 and the DNA sequence for DNA-PAINT imaging are reacted with a linker simultaneously, Wherein, the linker carries a first reactive group for reacting with the chimeric nanobody, and a second reactive group for reacting with a DNA sequence for DNA-PAINT imaging. Preferably, the first reactive group of the linker is a succinimide group, and the second reactive group is selected from an azide group, an alkynyl group, a dibenzocyclooctyne (DBCO) group, a trans-cyclooctene (TCO) group, a tetrazine (Tz) group, a bicyclo[6,1,0]nonynyl group, and an N-hydroxysuccinimide (NHS) group.
12. A kit comprising: the chimeric nanobody single-molecule localization imaging probe according to claim 9 or 10, and a DNA imaging strand with a fluorescent dye, wherein: The DNA imaging strand is a DNA sequence with a fluorescent dye and a quenching group at both ends, and its sequence is SEQ ID No.: 10 or SEQ ID No.: 11; the fluorescent dye is Cy3B or ATO643, and the quenching group is BHQ2 or BBQ650.
13. A method for performing DNA-PAINT super-resolution imaging, the method comprising the following steps: S1': fixed biological sample containing green fluorescent protein; S2': Block and permeabilize the fixed biological sample of S1'; S3': adding the chimeric nanobody single-molecule localization imaging probe in the kit as described in claim 12 to incubate the biological sample of S2'; S4': washing the biological sample of S3' with PBS buffer; and S5': adding the DNA imaging strand with fluorescent dye in the kit as claimed in claim 12 to the biological sample of S4' to perform single molecule localization super-resolution imaging, In particular, the biological sample is a cell, and the method is used to perform DNA-PAINT super-resolution imaging of organelles in the cell, and the organelles include: endoplasmic reticulum, nuclear pore complex, microtubule, Golgi, clathrin and mitochondria.
Citation Information
Patent Citations
Detection system
CN108732359A
Anti-HET-2 heavy chain antibody and application thereof
CN109627319A
DNA-PAINT-based detection method for PD-L1 protein on cell membrane and sequence
CN112798796A
Methods and compositions relating to super-resolution imaging and modification
US20160169903A1
Nanobody conjugates and protein fusions as bioanalytical reagents
US20180224459A1
